What was the overall valuation of the US clinical trials market in 2024?

The overall market valuation was $11.2 Billion in 2024. Read More

What is the projected market valuation for the US clinical trials market in 2035?

The projected valuation for 2035 is $18.0 Billion. Read More

What is the expected CAGR for the US clinical trials market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 4.41%. Read More

Which therapeutic area had the highest valuation in the US clinical trials market in 2024?

Oncology had the highest valuation at $4.5 Billion in 2024. Read More

What are the projected valuations for Phase III clinical trials by 2035?

The projected valuation for Phase III clinical trials is $7.2 Billion by 2035. Read More

Which study design segment is expected to grow the most by 2035?

The Interventional study design segment is expected to grow to $9.0 Billion by 2035. Read More

What was the valuation of the Contract Research Organizations segment in 2024?

The valuation of the Contract Research Organizations segment was $3.36 Billion in 2024. Read More

How much is the Expanded Access segment projected to be worth by 2035?

The Expanded Access segment is projected to be worth $4.0 Billion by 2035. Read More

Which key player had a notable presence in the US clinical trials market in 2024?

Covance, among others, had a notable presence in the US clinical trials market in 2024. Read More

What was the valuation of the Biotechnology Companies segment in 2024?

The valuation of the Biotechnology Companies segment was $3.36 Billion in 2024. Read More

US Clinical Trials Market

ID: MRFR/HC/14199-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

United States Clinical Trials Market Research Report: Size, Share, Trend Analysis By Phase (Phase 1, Phase 2, Phase 3, and Phase 4), By Study Design (Observational, Interventional, and Expanded Access), By Applications (Vaccine, Cell & Gene Therapy, Small Molecules, and Other Applications), By Indication (Autoimmune/Inflammation (Rheumatoid arthritis, Multiple Sclerosis, Osteoarthritis, Irritable Bowel Syndrome (IBS), Others), Pain Management (Chronic Pain, Acute Pain), Oncology (Blood Cancer, Solid Tumors, Other), CNS Condition (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Others), Diabetes, Obesity, Cardiovascular, Others), By Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Others), By Service Type (Protocol Designing, Patient Recruitment, Laboratory Services, Site Identification, Bioanalytical Testing Services), Cell-based Assays, Virology Testing, Method Development, Optimization, & Validation, Serology, Immunogenicity, & Neutralizing Antibodies, Biomarker Testing Services, PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services, Other Bioanalytical Testing Services), Analytical Testing Services, Clinical Trial Supply & Logistic Services, Clinical Trial Data Management Services, Decentralized Clinical Services, Medical Device Testing Services, and Others), By End Users (Hospital, Laboratories, and Clinics), Regions - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Phase (USD Billion)
  1. 4.1.1 Phase I
  2. 4.1.2 Phase II
  3. 4.1.3 Phase III
  4. 4.1.4 Phase IV
2. 4.2 Medical Device, BY Study Design (USD Billion)
  1. 4.2.1 Interventional
  2. 4.2.2 Observational
  3. 4.2.3 Expanded Access
3. 4.3 Medical Device, BY Therapeutic Area (USD Billion)
  1. 4.3.1 Oncology
  2. 4.3.2 Cardiology
  3. 4.3.3 Neurology
  4. 4.3.4 Infectious Diseases
  5. 4.3.5 Endocrinology
4. 4.4 Medical Device, BY End Use (USD Billion)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Biotechnology Companies
  3. 4.4.3 Contract Research Organizations
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Covance (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 IQVIA (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 PPD (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Charles River Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Medpace (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Syneos Health (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Parexel International (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Wuxi AppTec (CN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 KCR (PL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PHASE
3. 6.3 US MARKET ANALYSIS BY STUDY DESIGN
4. 6.4 US MARKET ANALYSIS BY THERAPEUTIC AREA
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY PHASE, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY PHASE, 2024 TO 2035 (USD Billion)
14. 6.14 MEDICAL DEVICE, BY STUDY DESIGN, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY STUDY DESIGN, 2024 TO 2035 (USD Billion)
16. 6.16 MEDICAL DEVICE, BY THERAPEUTIC AREA, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
18. 6.18 MEDICAL DEVICE, BY END USE, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY END USE, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PHASE, 2025-2035 (USD Billion)
  2. 7.2.2 BY STUDY DESIGN, 2025-2035 (USD Billion)
  3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Medical Device Market Segmentation

Medical Device By Phase (USD Billion, 2025-2035)

Phase I
Phase II
Phase III
Phase IV

Medical Device By Study Design (USD Billion, 2025-2035)

Interventional
Observational
Expanded Access

Medical Device By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Infectious Diseases
Endocrinology

Medical Device By End Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”